Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4056 | Training of youth, community health assistants and community health workers. Wiki | 1.00 |
| drug4053 | Training clinicians in basic critical care and the management of severe COVID-19 cases Wiki | 1.00 |
| drug2646 | OLO-1 Medical Molecular Sieve Oxygen Generator Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a multicenter, randomized, open, parallel-controlled study. Qualified subjects will randomly be assigned to the experimental arm or the control arm according to the ratio of 1:1, with age (> 60 years or ≤ 60 years), smoking status (yes/no) and forced expiratory volume in one second/prediction (FEV1 %pred > 60% or ≤ 60%) as the random stratification factors.
Description: The change from baseline in maximum oxygen consumption (VO2max) at maximum exercise load at Week 12 of treatment.
Measure: (VO2max) Time: The change from baseline in maximum oxygen consumption (VO2max) at maximum exercise load at Week 12 of treatment.Description: The change from baseline in maximum oxygen consumption (VO2max) at maximum exercise load at Week 4 of treatment.
Measure: (VO2max) Time: The change from baseline in maximum oxygen consumption (VO2max) at maximum exercise load at Week 4 of treatment.Description: The change from baseline in maximum oxygen consumption (VO2max) at maximum exercise load at Week 8 of treatment.
Measure: (VO2max) Time: The change from baseline in maximum oxygen consumption (VO2max) at maximum exercise load at Week 8 of treatment.Description: Differences in the change from baseline in ventilatory equivalent for carbon dioxide (VE /VCO2) at maximum exercise load at Week 4 of treatment.
Measure: (VE /VCO2) Time: Differences in the change from baseline in ventilatory equivalent for carbon dioxide (VE /VCO2) at maximum exercise load at Week 4 of treatment.Description: Differences in the change from baseline in ventilatory equivalent for carbon dioxide (VE /VCO2) at maximum exercise load at Week 8 of treatment.
Measure: (VE /VCO2) Time: Differences in the change from baseline in ventilatory equivalent for carbon dioxide (VE /VCO2) at maximum exercise load at Week 8 of treatment.Description: Differences in the change from baseline in ventilatory equivalent for carbon dioxide (VE /VCO2) at maximum exercise load at Week 12 of treatment.
Measure: (VE /VCO2) Time: Differences in the change from baseline in ventilatory equivalent for carbon dioxide (VE /VCO2) at maximum exercise load at Week 12 of treatment.Description: Differences in the change from baseline in ventilatory equivalent for oxygen (VE /VO2) at maximum exercise load at Week 4 of treatment.
Measure: (VE /VO2) Time: Differences in the change from baseline in ventilatory equivalent for oxygen (VE /VO2) at maximum exercise load at Week 4 of treatment.Description: Differences in the change from baseline in ventilatory equivalent for oxygen (VE /VO2) at maximum exercise load at Week 8 of treatment.
Measure: (VE /VO2) Time: Differences in the change from baseline in ventilatory equivalent for oxygen (VE /VO2) at maximum exercise load at Week 8 of treatment.Description: Differences in the change from baseline in ventilatory equivalent for oxygen (VE /VO2) at maximum exercise load at Week 12 of treatment.
Measure: (VE /VO2) Time: Differences in the change from baseline in ventilatory equivalent for oxygen (VE /VO2) at maximum exercise load at Week 12 of treatment.Description: Differences in the change from baseline in oxygen pulse (VO2 /HR) at maximum exercise load at Week 4 treatment.
Measure: (VO2 /HR) Time: Differences in the change from baseline in oxygen pulse (VO2 /HR) at maximum exercise load at Week 4 of treatment.Description: Differences in the change from baseline in oxygen pulse (VO2 /HR) at maximum exercise load at Week 8 of treatment.
Measure: (VO2 /HR) Time: Differences in the change from baseline in oxygen pulse (VO2 /HR) at maximum exercise load at Week 8 of treatment.Description: Differences in the change from baseline in oxygen pulse (VO2 /HR) at maximum exercise load at Week 12 of treatment.
Measure: (VO2 /HR) Time: Differences in the change from baseline in oxygen pulse (VO2 /HR) at maximum exercise load at Week 12 of treatment.Description: The change from baseline in the alveolar-arterial oxygen tension gradient (P (A-a) O2) at maximum exercise load at Week 4 of treatment.
Measure: (P (A-a) O2) Time: The change from baseline in the alveolar-arterial oxygen tension gradient (P (A-a) O2) at maximum exercise load at Week 4 of treatment.Description: The change from baseline in the alveolar-arterial oxygen tension gradient (P (A-a) O2) at maximum exercise load at Week 8 of treatment.
Measure: (P (A-a) O2) Time: The change from baseline in the alveolar-arterial oxygen tension gradient (P (A-a) O2) at maximum exercise load at Week 8 of treatment.Description: The change from baseline in the alveolar-arterial oxygen tension gradient (P (A-a) O2) at maximum exercise load at Week 12 of treatment.
Measure: (P (A-a) O2) Time: The change from baseline in the alveolar-arterial oxygen tension gradient (P (A-a) O2) at maximum exercise load at Week 12 of treatment.Description: The change from baseline in the arterial-to-end-tidal CO2 difference (P (a-et) CO2) at maximum exercise load at Week 4 of treatment.
Measure: (P (a-et) CO2) Time: The change from baseline in the arterial-to-end-tidal CO2 difference (P (a-et) CO2) at maximum exercise load at Week 4 of treatment.Description: The change from baseline in the arterial-to-end-tidal CO2 difference (P (a-et) CO2) at maximum exercise load at Week 8 of treatment.
Measure: (P (a-et) CO2) Time: The change from baseline in the arterial-to-end-tidal CO2 difference (P (a-et) CO2) at maximum exercise load at Week 8 of treatment.Description: The change from baseline in the arterial-to-end-tidal CO2 difference (P (a-et) CO2) at maximum exercise load at Week 12 of treatment.
Measure: (P (a-et) CO2) Time: The change from baseline in the arterial-to-end-tidal CO2 difference (P (a-et) CO2) at maximum exercise load at Week 12 of treatment.Description: The change from baseline in maximum exercise power at Week 4 of treatment.
Measure: maximum exercise power Time: The change from baseline in maximum exercise power at Week 4 of treatment.Description: The change from baseline in maximum exercise power at Week 8 of treatment.
Measure: maximum exercise power Time: The change from baseline in maximum exercise power at Week 8 of treatment.Description: The change from baseline in maximum exercise power at Week 12 of treatment.
Measure: maximum exercise power Time: The change from baseline in maximum exercise power at Week 12 of treatment.Description: The change from baseline in respiratory quotient (RER) at maximum exercise load at Week 4 of treatment.
Measure: RER Time: The change from baseline in respiratory quotient (RER) at maximum exercise load at Week 4 of treatment.Description: The change from baseline in respiratory quotient (RER) at maximum exercise load at Week 8 of treatment.
Measure: RER Time: The change from baseline in respiratory quotient (RER) at maximum exercise load at Week 8 of treatment.Description: The change from baseline in respiratory quotient (RER) at maximum exercise load at Week 12 of treatment.
Measure: RER Time: The change from baseline in respiratory quotient (RER) at maximum exercise load at Week 12 of treatment.Description: The change from baseline in total exercise duration at maximum exercise load at Week 4 of treatment.
Measure: The change from baseline in total exercise duration at maximum exercise load at Week 4 of treatment. Time: The change from baseline in total exercise duration at maximum exercise load at Week 4 of treatment.Description: The change from baseline in total exercise duration at maximum exercise load at Week 8 of treatment.
Measure: The change from baseline in total exercise duration at maximum exercise load at Week 8 of treatment. Time: The change from baseline in total exercise duration at maximum exercise load at Week 8 of treatment.Description: The change from baseline in total exercise duration at maximum exercise load at Week 12 of treatment.
Measure: The change from baseline in total exercise duration at maximum exercise load at Week 12 of treatment. Time: The change from baseline in total exercise duration at maximum exercise load at Week 12 of treatment.Description: The change from baseline in fingertip oxygen saturation (SpO2) at rest and without oxygen inhalation at Week 4 of treatment.
Measure: (SpO2) Time: The change from baseline in fingertip oxygen saturation (SpO2) at rest and without oxygen inhalation at Week 4 of treatment.Description: The change from baseline in fingertip oxygen saturation (SpO2) at rest and without oxygen inhalation at Week 8 of treatment.
Measure: (SpO2) Time: The change from baseline in fingertip oxygen saturation (SpO2) at rest and without oxygen inhalation at Week 8 of treatment.Description: The change from baseline in fingertip oxygen saturation (SpO2) at rest and without oxygen inhalation at Week 12 of treatment.
Measure: (SpO2) Time: The change from baseline in fingertip oxygen saturation (SpO2) at rest and without oxygen inhalation at Week 12 of treatment.Description: The change from baseline in the modified Medical Research Council (mMRC) Dyspnea Scale score at week 4 of treatment.
Measure: (mMRC) Time: The change from baseline in the modified Medical Research Council (mMRC) Dyspnea Scale score at week 4 of treatment.Description: The change from baseline in the modified Medical Research Council (mMRC) Dyspnea Scale score at week 8 of treatment.
Measure: (mMRC) Time: The change from baseline in the modified Medical Research Council (mMRC) Dyspnea Scale score at week 8 of treatment.Description: The change from baseline in the modified Medical Research Council (mMRC) Dyspnea Scale score at week 12 of treatment.
Measure: (mMRC) Time: The change from baseline in the modified Medical Research Council (mMRC) Dyspnea Scale score at week 12 of treatment.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports